NIH grant spurs universities, hospitals and clinics to joint effort
MORGANTOWN, W.Va. – Recommitting themselves to bring the benefits of research out of labs and hospitals and into the lives of West Virginia people and communities, a coalition of federal agencies, universities, hospitals and clinics will develop dozens of efforts over the next five years to battle addiction and cancer and reduce the impact of cardiovascular and neurological diseases.
A $20 million federal grant will be matched by $35.5 million in continued support from in-state partners to fund the program.
The West Virginia Clinical and Translational Science Institute (WVCTSI) has successfully competed for renewal funding from the National Institutes of Health (NIH) with a five-year $20 million grant to improve health outcomes in West Virginia. This grant provides five more years of funding, extending WVCTSI’s 2012 Institutional Development Award for Clinical and Translational Research (IDeA-CTR) through 2022.
“This funding will enable WVCTSI to reach a new level of statewide programming, supporting West Virginia investigators in academic medical centers and community clinics to find real solutions that will lead to better health for West Virginians,” said Sally Hodder, M.D., WVCTSI director and principal investigator.
“West Virginia University's mission to serve the state can't be met without strong links between our scientists, clinicians and the communities we serve. The biggest contributions that Dr. Hodder and all the partners in the Clinical and Translational Science Institute have made to our health are the thousands of connections they've created among researchers, doctors, nurses, and health professionals in dozens of communities across West Virginia,” said Clay Marsh, M.D., vice president and executive dean for health sciences at WVU. “Together, they are changing how research is done and changing the lives of people for the better."
With this new funding, WVCTSI will continue to offer funding and services to accelerate the creation and translation of new knowledge to impact health issues in rural communities. Additionally, WVCTSI has planned new programs and support, particularly for early career researchers starting their career in West Virginia. WVCTSI resources will be focused on five priority health areas including addiction and resulting emerging epidemics (such as hepatitis C), cancer, cardiovascular disease, chronic lung disease, and neurologic diseases.
“I am incredibly proud of the WVCTSI’s success and excited by the potential for impact that their research can have within West Virginia and beyond,” said Fred King, Ph.D., vice president for research at WVU. “West Virginia University and the WVCTSI have been integral to developing our state’s capacity as a national contender in biomedical research. The WVCTSI is also central to our University’s success in achieving recognition as a Highest Research Activity University, R1, in the Carnegie Classification of Institutions of Higher Education.”
Over the past five years WVCTSI has leveraged meaningful partnerships with academic and clinical institutions from across the state including WVU Medicine, the Charleston Area Medical Center, WVU (including regional campuses in Charleston and Martinsburg), and the West Virginia School of Osteopathic Medicine. WVCTSI is strengthened and enhanced by the addition of three new partners in the upcoming funding cycle including, Marshall University, the National Institute for Occupational Safety and Health, and the Department of Veterans Affairs.
Together, these organizations have committed an additional $35.5 million to WVCTSI, for a total funding commitment of $55.5 million over the next five years.
“We are excited about being part of the WVCTSI and contributing to this statewide initiative to support clinical and translational research. This program will provide research and collaborative opportunities for our faculty that could ultimately lead to improvements in health for all West Virginians. With our expertise in genomics, strong interest in addiction research and capacity for conducting clinical trials, Marshall will provide added strength to already strong program,” said Gary Rankin, Ph.D., vice dean for basic sciences at Marshall University.
Over the past five years of funding, WVCTSI created the state’s first Practice-Based Research Network (PBRN), a group of 74 primary care clinics (mostly rural) that has conducted 77 projects related to improving health in West Virginia. Many of these community projects have impacted the way rural healthcare providers treat patients.
“The PBRN with its many dedicated, talented healthcare providers, is truly one of the great achievements of the WVCTSI and is critical to improving health outcomes in West Virginia,” said Hodder. “Over the next five years the PBRN will continue to drive innovative and meaningful solutions to improve health in West Virginia.”
About the National Institutes of Health (NIH) and IDeA Program: NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. The IDeA program builds research capacities in states that historically have had low levels of NIH funding by supporting basic, clinical and translational research; faculty development; and infrastructure improvements. For more information about NIH and its programs, visit www.nih.gov.
West Virginia Clinical and Translational Science Institute
West Virginia University's Cancer Institute is well-known for its treatment and innovation. Leading the institute is Dr. Richard Goldberg, who has not only established himself as a transformative leader but also a potent researcher and educator.
Brian Boone, M.D., surgical oncologist in the WVU Medicine Department of Surgery and WVU Cancer Institute, performed the state’s first hyperthermic intraperitoneal chemotherapy (HIPEC) infusion. This treatment delivers heated, sterilized chemotherapy to the abdomen as a treatment for cancer that has spread to the lining of the abdominal cavity, or peritoneum.
WVU Medicine Obstetrics and Gynecology has experienced remarkable growth over the last two years. By increasing its team of gynecologic oncologists and adding a nurse practitioner, physician assistant, and genetic counselor, the department has expanded its capability to serve gynecologic cancer patients.